Serine market seen reaching $60.5 million by 2032

Allied Market Research says the global serine market will grow from $33.3 million in 2022 to $60.5 million by 2032, driven by dietary supplements, pharmaceuticals and animal feed demand. North America led the market in 2022, while Asia-Pacific is forecast to post the fastest growth.

Why it matters: - The serine market is expanding as manufacturers and formulators seek amino acid inputs for pharmaceuticals, supplements and animal nutrition. - Growth could reshape supply chains for a niche ingredient used across drug development, personal care and food applications. - The market’s projected rise to $60.5 million by 2032 signals steady but modest demand growth rather than a rapid scale-up.

What happened: - Allied Market Research published a report on the global serine market covering the period from 2023 to 2032. - The market was valued at $33.3 million in 2022 and is projected to reach $60.5 million by 2032. - The forecast implies a compound annual growth rate of 6.2% from 2023 to 2032. - The report covers product types including L Serine, D Serine and DL Serine. - The report also breaks the market down by end-use industry, including food and beverages, pharmaceuticals, cosmetics and personal care, agriculture, animal feed and nutrition, and others. - A sample brochure is available here. - The full summary report is available here.

The details: - The report names Ajinomoto, Evonik Industries, Kyowa Hakko Bio, Mitsui Chemicals, Merck KGaA, Thermo Fisher Scientific, Suvchem, Shanghai Brightol International, Sichuan Tongsheng Amino Acid and Tokyo Chemical Industry as leading market players. - Market participants are using new product launches, collaborations, expansion, joint ventures and agreements to defend or grow share. - Demand is rising from dietary supplements and the pharmaceutical industry, where serine supports drug development. - Serine substitutes are limiting growth to some extent. - Animal feed demand is creating additional expansion opportunities. - The Russia-Ukraine war disrupted transport routes and infrastructure, which affected raw material and finished-product availability. - The conflict also created price volatility and uncertainty around investment decisions. - Some manufacturers shifted sourcing to countries outside the conflict zone to reduce supply risk. - L Serine held nearly three-fifths of global revenue in 2022 and is projected to post the fastest growth among product types, at 6.4% CAGR. - L Serine is a non-essential amino acid and one of the 20 standard amino acids used by cells to build proteins. - L Serine is involved in the synthesis of proteins, nucleotides and phospholipids. - Pharmaceuticals held more than two-fifths of global revenue in 2022 and is expected to remain the largest end-use segment. - Pharmaceuticals is also projected to be the fastest-growing end-use category, at 6.6% CAGR. - Serine is used in antiviral medications, cardiovascular drugs and anticancer treatments. - Serine is also used in formulations targeting neurological disorders and metabolic diseases. - North America accounted for around two-fifths of global revenue in 2022 and is expected to remain the largest regional market through 2032. - North American demand is being supported by serine use in pharmaceuticals, cosmetics and food and beverages. - Serine is used as a precursor in personal care products, including anti-aging creams and hair care formulations. - The Asia-Pacific region is projected to grow fastest, at 6.7% CAGR. - A detailed company contact and social media links were included in the release.

Between the lines: - The report points to a market that is concentrated in higher-value applications, especially pharmaceuticals, rather than mass consumer use. - The fastest-growing segments suggest future demand will come from specialty uses where serine’s biochemical role is harder to substitute. - Supply chain sensitivity remains a risk, especially for a market that can be affected by geopolitical disruption and raw-material constraints.

What’s next: - L Serine is expected to remain the dominant product type through 2032. - Pharmaceuticals are expected to stay the leading end-use segment through 2032. - North America is expected to keep the largest revenue share, while Asia-Pacific is expected to outpace other regions in growth. - Market players are likely to continue using partnerships, expansions and product launches to compete in the space.